
‘Gargantua' deep-sea creature among new species found in Atlantic. See them
In the depths of the Mid-Atlantic Ridge, underwater volcanoes spew material into the ocean water.
Vents that connect underground rifts to the surface release billowing clouds of black deposits of iron sulfide, earning the moniker 'black smoker chimneys.'
These hydrothermal vent fields are hot, chemically rich and toxic to most forms of life. But, a special few organisms have adapted to call them their home.
Now, two new species found around the black smoker chimneys of the Hydra and Falkor hydrothermal vent fields have been identified — and they're huge.
Researchers operating the remote underwater vehicle SuBastian, from the Schmidt Ocean Institute, and the human-occupied vehicle Nautile, from the French Institute of Research and Exploitation of the Sea, used suctioning tools to collect peltospirid gastropods from the black smokers, according to a study published June 5 in the peer-reviewed Zoological Journal of the Linnean Society.
The peltospirid gastropods, or a family of marine snails found around hot vents, were compared to known species, but their 'very large' size immediately tipped off researchers that they may belong to new species.
Genetic testing confirmed their suspicions, according to the study.
The first new species, Peltospira gargantua, was found on a black smoker chimney in the Hydra field at a depth of about 12,300 feet, researchers said.
With a shell smaller than an inch, the snail is 'very large' compared to others in their genus, researchers said. The shell is 'rather tightly coiled,' and their bodies have 'short, paddle-like' tentacles.
Part of the shell is an 'olive green' color, but the shells are typically 'obscured by dark brown to reddish layers of' mineral deposits, according to the study.
'The head is large, with a thick and broad snout that expands slightly towards the mouth,' researchers said of the snail's body. The animals have no trace of eyes on their external bodies, not uncommon for creatures found in the dark abyss of the Atlantic.
Researchers named the species after Gargantua, a character from the French novels 'The Five Books of the Lives and Deeds of Gargantua and Pantagruel,' stories of a giant king and his son.
'The word Gargantua has since been used to mean 'huge' or 'immense,' as exemplified by the English adjective gargantuan,' according to the study. 'Thus, the species name refers to the very large size of the new species in relationship to other known (relatives).'
The second new species, from a different genus, was named after Gargantua's son, Pantagruel, according to the study.
Lirapex pantagruel is the 'largest of all known Lirapex species, hence the name of a giant is fitting,' researchers said.
The species was found on the black smokers of the Falkor hydrothermal vents at a depth of about 13,000 feet, according to the study.
This species is even smaller, with a shell diameter of about 0.3 inches long, and the shell is 'tightly coiled,' researchers said.
The pantagruel snail is also covered in reddish to blackish material, but has a semi-transparent and greenish hue otherwise.
'The soft parts are overall typical of the genus Lirapex,' researchers said. 'The head is large and without pigmented eyes… The snout is short, flattened, with the mouth opening ventrally. A pair of thin, film-like jaws are present.'
Finding the two new species was a 'surprising discovery,' researchers said, as the areas where they live have only been explored for a few years.
'Hydrothermal vents on the northern (Mid-Atlantic Ridge) have been explored for about four decades. Yet, species of large snails aggregating in conspicuous habitats near hot fluid orifices, such as P. gargantua and L. pantagurel, have remained undiscovered until now,' researchers said. 'It might be that the two new species are present only in Hydra and Falkor EMARK, two vent fields that were found only in 2023.'
The research team includes Chong Chen, Florence Pradillon, Coral Diaz-Recio Lorenzo and Joan Manel Alfaro-Lucas.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CBS News
4 hours ago
- CBS News
Underwater military drone accidentally stumbles upon deepest shipwreck ever found off France: "As if time froze"
What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks What technology could change the way we learn about shipwrecks Archaeologists have discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France, the deepest such find in its section of the Mediterranean or any other French waters. Archaeologists believe the ship was sailing from northern Italy loaded with ceramics and metal bars before it sunk. Despite a little modern waste dotting its sunken cargo at 8,422 feet below sea level, researchers were excited about the potential of an archaeological site largely preserved intact. "It's the deepest shipwreck ever found in French territorial waters," Arnaud Schaumasse, the head of the culture ministry's underwater archaeology department, said late Wednesday. France's Department of Underwater and Submarine Archaeological Research released images of the shipwreck on social media, saying the vessel was discovered "during a military operation to explore the seabed." Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research An underwater drone stumbled upon the sunken ship by chance in early March in waters near Saint-Tropez in southeastern France, deputy maritime prefect Thierry de la Burgade said. "The sonar detected something quite big, so we went back with the device's camera, then against with an underwater robot to snap high-quality images," he said. The drone was patrolling the seabed as part of a government project to explore and monitor France's deep-sea resources, from minerals to deep-sea internet cables. Archaeologist Marine Sadania said experts discovered 200 jugs with pinched spouts among the wreckage at the site they have dubbed "Camarat 4." Some of these jugs were marked with the monogram "HIS," the first three letters of the Greek name of Jesus, or covered with plant-inspired or geometric patterns. Those details seemed to indicate the jugs hailed from the Liguria region in what is now northern Italy, she said. "Camarat 4 is a remarkable discovery for its depth, unprecedented character and the opportunity it offers to study an almost intact 16th-century wreck," France's Department of Underwater and Submarine Archaeological Research said. "As if time froze" Experts also identified piles of around 100 yellow plates, two cauldrons, an anchor and six cannons. Modern waste, such as a soda can or an empty yogurt container, were spotted too. One image released by officials appeared to show an aluminum can next to an anchor. Archaeologists say they discovered by chance what they say are the remains of a 16th-century merchant ship more than 1.5 miles underwater off southern France. National Navy via France's Department of Underwater and Submarine Archaeological Research But despite this, "the site -- thanks to its depth which prevented any recovery or looting -- has remained intact, as if time froze, which is exceptional," Sadania said. Over the coming two years, she and colleagues plan to draw up a 3D digital version of the ship, as well as extract samples from the site to better study them before returning them to the public domain. According to the defense ministry in charge of exploring France's deep seas, researchers can remove an item from a shipwreck by guiding a submarine robot with pincers or arms, via a long cable linking the device to a boat on the surface. Officials said further analysis will be carried out by ceramic experts, archaeologists and specialists in naval architecture. The deepest French authorities had found a sunken vessel until now was 2.3 kilometers under sea level off the southern city of Toulon in 2019. The wreckage belonged to La Minerve, a French submarine that plunged to its demise in 1968 with 52 navy crew on board, only four minutes after the start of a routine assignment.
Yahoo
7 hours ago
- Yahoo
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025 Opening of AAC targeted for Q4 2025 at the latest Multiple near-term value catalysts expected over next 12 months PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. "We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. " Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Q3 2025: Clinical trial application for focused dose-ranging study Q4 2025: Completion of manufacturing tech transfer Q4 2025: Opening of the AAC program Q2 2026: Completion of Phase III trial preparations Early H2 2026: Initiation of global Phase III clinical trial Early H2 2026: pre-submission meeting with MHRA Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release. View source version on Contacts GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@


Business Wire
7 hours ago
- Business Wire
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ ® Named Early Access Program (AAC) in France
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ ® upon approval of a dose-ranging clinical study. Clear Path Forward for LUMEVOQ ® AAC Program in France Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025. In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest. "In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics."We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment." Financing Strategy to Support Regulatory Milestones GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones. ' We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study,' commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities." Advancing Core Marketing Authorization Strategy In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy: Preparation for regulatory consultations in the US and EU Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply Advancing preparations for MHRA submission in the United Kingdom During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities. Multiple Value Catalysts GenSight anticipates a number of significant value-creating events in 2025-2026: Financial Position The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025. The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ ®. As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares. Risk factors Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website ( and/or AMF ( The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1. About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.